Evidence map›Paper›PMID 24736801›Full record

Trial reportAmerican journal of Alzheimer's disease and other dementias2014

Psychometric properties of the Dependence Scale in large randomized clinical trials of patients with mild and moderate Alzheimer's disease.

Kathleen W Wyrwich, Priscilla Auguste, Jacqui Buchanan, Katja Rudell, Loretto Lacey, Christopher Leibman, Tara Symonds, H Robert Brashear

Abstract readMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in American journal of Alzheimer's disease and other dementias, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. A Path Analysis of Dependence and Quality of Life in Alzheimer's Disease.American journal of Alzheimer's disease and other dementias · 2017
    Observational
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Kathleen W WyrwichEvidera (formerly United BioSource Corporation), Bethesda, MD, USA kathy.wyrwich@evidera.com.
Priscilla AugusteEvidera (formerly United BioSource Corporation), Bethesda, MD, USA.
Jacqui BuchananJanssen Alzheimer Immunotherapy, San Francisco, CA, USA.
Katja RudellPfizer Patient-Reported Outcomes Centre of Excellence, Surrey, United Kingdom.
Loretto LaceyJanssen Alzheimer Immunotherapy, San Francisco, CA, USA.
Christopher LeibmanJanssen Alzheimer Immunotherapy, San Francisco, CA, USA.
Tara SymondsPfizer Patient-Reported Outcomes Centre of Excellence, Surrey, United Kingdom.
H Robert BrashearJanssen Alzheimer Immunotherapy, San Francisco, CA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThe need for assistance from others is a hallmark concern in Alzheimer's disease (AD). The psychometric properties of the Dependence Scale (DS) for measuring treatment benefit were investigated in large randomized clinical trials of patients with mild to moderate AD.

methodsReliability, validity, and responsiveness of the DS were examined. Path models appraised relationships and distinctiveness of key AD measures. The responder definition was empirically derived.

resultsGenerally acceptable reliability (α ≥ .65), significant (P < .001) known-groups tests, and moderate to strong correlations (r ≥ .31) confirmed the DS psychometric properties. Path models supported relationships and distinctiveness of key AD measures. A DS change of ≤ 1 point for patients with limited home care and ≤ 2 points for patients with assisted living care best described stability of the level of dependence on caregivers.

conclusionThe DS is a psychometrically robust measure in mild to moderate AD. The empirically derived responder definition aids in the interpretation of DS change.

Indexed as

Disability EvaluationPsychometricsActivities of Daily LivingAgedAged, 80 and overAlzheimer DiseaseAntibodies, Monoclonal, HumanizedCross-Sectional StudiesDouble-Blind MethodFemaleGeriatric AssessmentHumansLongitudinal StudiesMaleMiddle AgedNeuropsychological TestsAntibodies, Monoclonal, HumanizedbapineuzumabAlzheimer’s diseasecaregiverdependenceinterpretationpsychometric propertiesresponder definition

Identifiers

PMID24736801
PMCPMC10852768

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.